ARTICLE | Clinical News

Lorvotuzumab mertansine: Phase I data

November 1, 2010 7:00 AM UTC

Data from a dose-escalation Phase I trial in 45 eligible patients with CD56+ solid tumors showed that 4-94 mg/m 2 IMGN901 reduced tumor volume by 1.3-100% in 13 (29%) patients, with an additional 10 patients having no increase in tumor volume. In 13 patients with metastatic Merkel cell carcinoma, 60 mg/m 2 IMGN901 produced 1 complete response (CR), 1 partial response (PR) that evolved into a CR and 3 cases of stable disease. In 26 patients with small cell lung cancer (SCLC), IMGN901 produced 3 cases of stable disease and 1 unconfirmed PR. A total of 64 patients have been enrolled. Data were presented at the European Society for Medical Oncology meeting in Milan. ...